(R,S)-AM1241
SIGMA/A6478 - ≥98% (HPLC), solid
Synonym: (R,S)
CAS Number: 444912-48-5
Empirical Formula (Hill Notation): C22H22IN3O3
Molecular Weight: 503.33
MDL Number: MFCD11045986
Linear Formula: C22H22IN3O3
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | yellow |
| drug control | regulated under CDSA - not available from Sigma-Aldrich Canada |
| form | solid |
| InChI | 1S/C22H22IN3O3/c1-24-11-5 |
| InChI key | ZUHIXXCLLBMBDW-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | CN1CCCCC1Cn2cc(C(=O)c3cc( |
| solubility | DMSO: ~18 mg/mL at 60 °C |
| Application: | (R,S)-AM1241 has been used as a cannabinoid CB2 agonist: • to study its inhibitory effect on bone cancer-induced pain and bone loss • to study the effect of its interaction with 17βestradiol on proliferation activity in primary human osteoblasts • to evaluate the sites of CB2 mediated antinociception in vivo. |
| Biochem/physiol Actions: | AM1241 acts as an antinociceptive agent in several animal pain models. It has a potential to delay disease progression in amyotrophic lateral sclerosis (ALS) mouse model. Intrathecal, intravenous or intraperitoneal administration of AM1241 reduces hyperalgesia and allodynia in neuropathic rats. |
| Biochem/physiol Actions: | Selective CB2 cannabinoid receptor agonist |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | ![]() GHS07,GHS08 |
| Signal word | Danger |
| Hazard statements | H315 - H319 - H334 - H335 |
| Precautionary statements | P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xn |
| Risk Statements | 36/37/38-42/43 |
| Safety Statements | 22-26-36/37-45 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |



